Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 50,716 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 50,716 shares of Akero Therapeutics stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.57, for a total value of $1,601,104.12. Following the sale, the chief operating officer now directly owns 216,286 shares of the company's stock, valued at approximately $6,828,149.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jonathan Young also recently made the following trade(s):

• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total transaction of $281,800.00.
• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total transaction of $14,870.24.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock traded up $0.69 during trading on Tuesday, reaching $32.74. The company's stock had a trading volume of 463,982 shares, compared to its average volume of 872,131. The business's 50-day moving average price is $28.54 and its 200-day moving average price is $24.97. The firm has a market cap of $2.27 billion, a PE ratio of -9.60 and a beta of -0.26. Akero Therapeutics, Inc. has a 52 week low of $13.39 and a 52 week high of $37.00. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.09. Equities analysts forecast that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AKRO. Janus Henderson Group PLC raised its stake in Akero Therapeutics by 42.2% during the first quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company's stock worth $154,589,000 after acquiring an additional 1,815,569 shares in the last quarter. Redmile Group LLC increased its stake in shares of Akero Therapeutics by 67.5% in the first quarter. Redmile Group LLC now owns 1,858,702 shares of the company's stock valued at $46,951,000 after buying an additional 749,226 shares during the period. Vanguard Group Inc. increased its stake in shares of Akero Therapeutics by 19.0% in the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company's stock valued at $92,702,000 after buying an additional 584,875 shares during the period. Long Focus Capital Management LLC increased its stake in shares of Akero Therapeutics by 119.0% in the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company's stock valued at $16,882,000 after buying an additional 391,000 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Akero Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company's stock valued at $102,569,000 after buying an additional 384,555 shares during the period.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Akero Therapeutics in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.20.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.